The interaction of the diltiazem with oral and intravenous cyclosporine in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2004, Pages 119-123

  Kalkan, Sule ^a   Gumustekin, Mukaddes ^a   Aygoren, Oguz ^a   Tuncok, Yesim ^a   Gelal, Ayse ^a   Guven, Hulya ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Cyclosporine; Diltiazem; Interaction; Metabolism; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; DILTIAZEM;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; NONHUMAN; NONPARAMETRIC TEST; RAT;

EID: 3042626779     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190586     Document Type: Article

References (36)

1. Combalbert, J., Fabre I., Fabre G., Dalet I., Derancourt J., Cano J.P., Maurel P. (1989): Metabolism of cyclosporin A; IV: purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug. Metab. Dispos., 17, 197-207.
2. Kronbach T., Fischer V., Meyer U.A. (1988): Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther., 43, 630-635.
3. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., Watkins P.B. (1992): Identification of rifampin-inducible P450IIIA4(CYP3A4) in human small bowell enterocytes. J. Clin. Invest., 90, 1871-1878.
4. Kolars J.C., Awni W.M., Merion R.M., Watkins P.B. (1991): First-pass metabolism of cyclosporin by the gut. Lancet., 338, 1488-1490.
5. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Wacher V.J. (1995): Differentiation of absorption and first pass gut and hepatic metabolism in humans:Studies with cyclosporine. Clin. Pharmacol. Ther., 58, 492-497.
6. Quijano R.F., Ohnishi N., Umeda K., Komada F., Iwakawa S., Okumura K. (1993): Effect of atropine on gastrointestinal motility and the bioavailability of cyclosporine A in rats. Drug. Metab. Dispos., 21, 141-143.
7. Hebert M.F., Roberts J.P., Prueksaritanont T., Benet L.Z. (1992): Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther., 52, 453-457.
8. Wu C.Y., Hebert M.F., Benet L.Z. (1993): Use of iv and oral drug levels from cyclosporine (CsA) with concomitant rifampin to differentiate gut absorption and metabolism [Abstract]. Pharm. Res., 10, S-345.
9. First M.R., Schroeder T.J., Alexander J.W., Stephens G.W., Weiskittel P., Myre S.A., Pesce A.J. (1991): Cyclopsporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation., 51(2), 365-370.
10. Keogh A., Spratt P., McCosker C., Macdonald P., Mundy J., Kaan A. (1995): Ketoconazole to reduce the need for cyclosporin after cardiac transplantation. N. Engl. J. Med., 333,628-633.
11. Slaughter R.L., Edwards D.J. (1995): Recent advances: The cytochrome P450 enzymes. Ann. Pharmacother., 29, 619-624.
12. Bagnis C., Deray G. (1998): Calcium inhibitors in the management of hypersentive patients on cyclosporine. Arch. Mal. Coeur. Vaiss., 91(4), 411-414.
13. Yee G.C., McGuire T.R. (1990): Pharmacokinetics drug interactions with cyclosporin (Part II). Clin. Pharmacokinet., 19(5), 400-415.
14. Maggio T.G., Bartels D.W. (1988): Increased cyclosporine blood concentrations due to verapamil administration. Drug. Intell. Clin. Pharm., 22(9), 705-707.
15. Kessler M., Netter P., Renoult E., Jonon B., Mur J.M., Trechot P., Dousset B. (1989): Influence Of nicardipine on renal function and plasma cyclosporin in renal transplant patients. Eur. J. Clin. Pharmacol., 36, 637-638.
16. Spoendlin M., Peters J., Welker H., Bock A., Thiel G.(1998): Pharmacokinetics interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol. Dial. Transplant., 13(7), 1787-1791.
17. Yee G.C., McGuire T.R. (1990): Pharmacokinetics drug interactions with cyclosporin (Part I). Clin. Pharmacokinet., 19(4), 319-332.
18. Martinez F., Pirson Y., Wallemacq P., van Ypersele de Strihou C. (1991): No clinically significant interaction between ciclosporin and isradipine. Nephron., 59(4), 658-659.
19. Jones T.E., Morris R.G., Mathew T.H. (1997): Diltiazem-cyclosporin pharmacokinetic interaction-dose-response relationship. Br. J. Clin. Pharmacol., 44, 499-504.
20. Smith C.L., Hampton E.M., Pederson J.A., Pennington L.R., Bourne D.W.(1994): Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy., 14(4), 471-481.
21. Jones T.E., Morris R.G. (1996): Diltiazem does not always increase blood cyclosporin concentration. Br. J. Clin. Pharmacol., 42, 642-644.
22. Koleva M.R., Stoychev T.S. (1995): Effects of nifedipine, verapamil and diltiazem on the enzyme-inducing activity of phenobarbital and beta-naphthoflavone. Gen. Pharmacol., 26(1), 225-228.
23. Hedayati S., Bernareggi A., Rowland M. (1991): Absorption kinetics of cyclosporin in rats. J. Pharm. Pharmacol., 43, 122-124.
24. Lindberg-Freijs A., Karlsson M.O. (1994): Dose dependent absorption and linear disposition of cyclosporin a in rat. Biopharm. Drug. Dispos., 15(1), 75-85.
25. Bernareggi A., Rowland M. (1991): Physiologic modeling of cyclosporin kinetics in rat and man. J. Pharmacokinet. Biopharm., 19(1), 21-50.
26. Ohba M., Ohnishi N., Komada F., Iwakawa S., Okumura K. (1996): Effects of Clarithromycin on the bioavailability of cyclosporin in rats. Biol. Pharm. Bull., 19(5), 733-737.
27. Murray M., Butler A.M.(1996): Enhanced inhibiton of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J. Pharmacol. Exp. Ther., 279, 1447-1452.
28. Sutton D., Butler A.M., Nadin L., Murray M. (1997): Role of CYP3A4 in human hepatic diltiazem N-demethylation:inhibiton of CYP3A4 activity by oxidized diltiazem metabolites. J. Pharmacol. Exp. Ther., 282(1), 294-300.
29. Maenpaa J., Ruskoaho H., Pelkonen O. (1989): Inhibiton of hepatic microsomal drug metabolism in rats by five calcium antagonists. Pharmacol. Toxicol., 64(5), 446-50.
30. Brage R., Cortijo J., Esplugues J., Esplugues J.V., Marti-Bonmati E., Rodriguez C. (1986): Effects of calcium channel blockers on gastric emptying and acid secretion of the rat in vivo. Br. J. Pharmacol., 89, 627-633.
31. Wadhwa N.K., Schroeder T.J., O'Flaherty E., Pesce A.J., Myre S.A., First M.R. (1987): The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation., 43(2), 211-213.
32. Ueda C.T., Lemaire M., Gsell G., Misslin P., Nussbaumer K. (1984): Apparent dose-dependent oral absorption of cyclosporin a in rats. Biopharm. Drug. Dispos., 5, 141-151.
33. Wacher V.J., Wong S., Wong H.T. (2002): Peppermint oil enhances cyclosporine oral bioavailability in rats: Comparison with D-α-tocopheryl poly(ethylene glycol 1000) Succinate (TPGS) and ketoconazole. J. Pharm. Sci., 91(1), 77-90.
34. Whalen R.D., Tata P.N.V., Burckart G.J., Venkataramanan R. (1999): Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica., 29, 3-9.
35. Ptachcinski R.J., Venkataramanan R., Burckart G.J. (1986): Clinical pharmacokinetics of cyclosporin. Clin. Pharmacokinet., 11(2), 107-132.
36. Wagner O., Schreier E., Heitz F., Maurer G. (1987): Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug. Metab. Dispos., 15(3), 377-383.